HYPOXIA ENHANCES THE EXPRESSION OF AUTOCRINE MOTILITY FACTOR AND THE MOTILITY OF HUMAN PANCREATIC CANCER CELLS

Hiroto Niizeki¹,², Masanobu Kobayashi¹*, Iori Horiuchi¹, Nobuaki Akakura¹,³, Jian Chen¹,², Jingxin Wang¹, Jun-ichi Hamada¹, Prem Seth⁵, Hiroyuki Katoh⁵, Hideomi Watanabe⁶, Avraham Raz⁷, and Masuo Hosokawa¹

¹Division of Cancer Pathobiology, ²Division of Cancer-Related Genes, ³Division of Gene Therapy Development, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, ²Department of Surgical Oncology, ³Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Department of Orthopedic Surgery, ⁵Gunma University, Maebashi, ⁷Division of Basic Research, KARMANOS Cancer institute, Wane State University school of Medicine, Detroit, MI.

A running title: AMF expression promoted by hypoxia

* Correspondence to Dr. M Kobayashi, Division of Cancer Pathobiology, Institute for Genetic Medicine, Hokkaido University, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638 Japan Fax; 81-11-706-7826, Tel; 81-11-706-5070, e-mail; mkobaya@med.hokudai.ac.jp
Summary

The incidence of distant metastases is higher in the tumors with low oxygen pressure than in those with high oxygen pressure. It is well known that hypoxia induces the transcription of various genes involved in angiogenesis and anaerobic metabolism necessary for the growth of tumor cells in vivo, suggesting that hypoxia may also induce the transcription of metastasis-associated genes. We sought to identify the metastasis-associated genes differentially expressed in tumor cells under hypoxic conditions with the use of a DNA microarray system. We found that hypoxia enhanced the expression of autocrine motility factor (AMF) mRNA in various cancer cells and also enhanced the random motility of pancreatic cancer cells. AMF inhibitors abrogated the increase of motility under hypoxic conditions. In order to explore the roles of hypoxia-inducible factor-1α (HIF-1α), we established HIF-1α-transfectants and dominant negative HIF-1α-transfectants. Transfection with
HIF-1α and dominant-negative HIF-1α enhanced and suppressed the expression of AMF/PHI/NL mRNA and the random motility, respectively. These results suggest that hypoxia may promote the metastatic potential of cancer cells through the enhanced AMF/PHI/NL mRNA expression and that the disruption of the HIF-1 pathway may be an effective treatment for metastasis.

Key words: hypoxia, AMF, motility, HIF-1, metastasis
INTRODUCTION

As metastasis is the major cause of death in cancer patients, control of metastasis is most important in the therapies for cancer patients. In order to control metastasis, we need to understand the details of metastatic process that is now thought to take multiple steps. Although a variety of factors have been documented to play important roles in the metastatic steps (Poste et al., 1980; Liotta, 1986; Liotta, 1988; Nicolson, 1988), many factors are yet to be elucidated. Several clinical investigations demonstrated that patients with hypoxic tumors had poor prognoses and that the incidence of distant metastases was higher in the tumors with low oxygen pressure than in those with high oxygen pressure (Gatenby et al., 1988; Brizel et al., 1996; Hockel et al., 1998; Rofstad, 2000). These studies suggest that the tumor cells exposed to hypoxia at the primary tumor sites acquire aggressive properties including metastatic
potential more than the well-oxygenated tumor cells do. In fact, recent reports have demonstrated that hypoxia enhances the expression of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) in tumor cells, resulting in an increase of metastatic potential (Claffey et al., 1996; Shi et al., 1999; Biroccio et al., 2000). However, it remains poorly understood how hypoxia promotes tumor cells’ metastatic potential.

When tumor cells are exposed to hypoxia, hypoxia-inducible factor-1 (HIF-1), which is a transcription factor composed of HIF-1α and HIF-1β subunits (Wang et al., 1995; Wang et al., 1996), is activated and then it promotes the transcription of several genes such as glucose transporters, glycolytic enzymes, and angiogenic factors (Dang et al., 1999). A recent report demonstrates that human common cancer cells over-express hypoxia-inducible factor-1α (HIF-1α) in vivo and that the expression of HIF-1α is associated with metastasis (Zhong et
al., 1999). Furthermore, infiltration of endothelial cells, which involves various factors, is enhanced when tumor tissues are in hypoxia-induced angiogenesis. These reports have prompted us to hypothesize that hypoxia may also promote the invasion and metastasis of tumor cells by promoting the expression of metastasis-associated genes in addition to angiogenic factors through the activation of HIF-1α. As hypovasculature is an outstanding characteristic of pancreatic cancers with high invasiveness and metastatic potential (Raijiman et al., 1995) and most of pancreatic cancer cells over-express HIF-1α protein (Akakura et al., 2001), we speculate that pancreatic cancer cells may be exposed to severe hypoxia in vivo and that pancreatic cancers express higher levels of metastasis-associated genes in addition to angiogenic factors than well-oxygenated tumor cells do. Therefore we examined the expression of more than 9,000 mRNAs in a pancreatic cancer cell
line under hypoxic and non-hypoxic conditions with the use of a DNA microarray system and compared them to identify the metastasis-associated genes induced by hypoxia.

We found that autocrine motility factor (AMF) / phosphohexose isomerase (PHI) / neuroleukin (NL) mRNA was expressed more highly in the cells under hypoxic conditions than under non-hypoxic conditions. In this study, we examined the expression of AMF/PHI/NL mRNA in a variety of cancer cell lines and the random motility of a pancreatic cancer cell line under hypoxic and non-hypoxic conditions, because AMF/PHI/NL was reported to stimulate random motility (Liotta et al., 1986). Furthermore, we established HIF-1α-transfectants and dominant-negative HIF-1α-transfectants and examined their expression of AMF/PHI/NL mRNA and random motility in order to determine the possible role of HIF-1α in the AMF/PHI/NL mRNA expression and random motility promoted by hypoxia.
MATERIALS AND METHODS

Cell lines:

Pancreatic ductal adenocarcinoma cell lines (PCI-6, PCI-10, PCI-19, PCI-43 and PCI-66 cells) were established from surgically resected pancreatic cancer tissues. These cell lines were kindly supplied from Dr. Hiroshi Ishikura (The First Department of Pathology, Hokkaido University School of Medicine) and maintained in DMEM/F12 medium supplemented with 10 % fetal calf serum (FCS). TAOV (ovarian cancer), TTOV (ovarian cancer), HepG2 (hepatoma), PC-6 (lung cancer), MiaPaca-2 (pancreatic cancer), BxPC-3 (pancreatic cancer) and KM-12 (colon cancer) cells were maintained in DMEM medium supplemented with 10 % FCS.

DNA microarray analysis:

Total RNA was extracted with the use of TRIZOL Reagent (LIFE TECHNOLOGIES, Tokyo, Japan) from the PCI-10 cells that had been incubated for 24 h under non-hypoxic and hypoxic conditions.
The incubation under hypoxic condition (1 % O₂) was done in a hypoxic chamber gassed with 95 % N₂ and 5 % CO₂ (Wakenyaku Co. Ltd., Tokyo). mRNA was purified from the total RNA with the use of a Quickprep mRNA purification kit (Amersham Pharmacia Biotech, Tokyo, Japan). Differentially expressed genes were screened with the use of a DNA microarray system, UniGEM human (KURABO INDUSTRIES LTD, Osaka, Japan). We defined the genes expressed at more than 2-fold higher levels under hypoxic conditions than under non-hypoxic conditions as possible hypoxia-inducible genes in this study.

Establishment of HIF-1α-transfectants and dominant negative HIF-1α-transfectants:

Establishment of HIF-1α-transfectants was previously reported (Akakura et al., 2001). A cDNA for dominant negative HIF-1α (dnHIF-1α) lacking both the DNA binding and transactivation domains of HIF-1α was amplified from reverse
transcription (RT) products of mRNAs purified from the PCI-10 cells and cloned into PCR4-TOPO (Invitrogen, Carlsbad, CA). PCR primers for dominant negative HIF-1α were selected as previously described (Halterman et al., 1999) (forward, ccgctcgagaccatgcgaaggaaagaatctg; reverse, ggggtacctcattgtcaagaggctact). Plasmids were recovered, purified and sequenced with a DyeDeoxy Terminator kit (Perkin-Elmer, Urayasu, Japan) on an ABI 377 automated sequencer (Applied Biosystems, Urayasu, Japan) in the condition described in the manufacturer’s protocol. Cloned fragments were recovered from the vectors and ligated into PcDNA3.1+ (Invitrogen, Carlsbad, CA). PCI-43 cells were transfected with the expression vector for dnHIF-1α with the use of Lipofectamine (Life Technologies, Tokyo, Japan). Transfectants were cloned by a limiting dilution method after the selection with G-418 at 800 μg/ml. The transfectants were maintained in the presence
of 400 µg/ml of G-418.

FACS analysis:

Cells were stained with anti-AMFR antibody (rat monoclonal antibody, IgM) (Niinaka et al., 1998) for 1 h and then stained with second anti-rat Ig antibody for 1 h. Expression of AMFR proteins was quantified with the use of FACScaliber (Becton Dickinson, Mountain View, CA).

Northern blot analysis:

Northern blot analysis was performed by the method described previously (Choi et al., 2000). Total RNA (20 µg) was separated by electrophoresis in 1.2% denaturing formaldehyde-agarose gels. The RNA was transferred to nylon membrane (Hybond N’, Amersham) overnight by capillary elution and UV cross-linked. After prehybridization of the blots for 1-2 hr at 42 °C in hybridization buffer (5XSSPE, 5Xdenhardt’s solution, 1% SDS, 50% Formamide and 0.1 mg/ml of denatured salmon sperm DNA), the membrane was hybridized overnight at 42 °C with the cDNA probes for AMF and
AMF receptor (AMFR). The probed membrane was then washed and exposed to radiographic film. cDNA fragments for AMF and AMF receptor (AMFR) were amplified by RT-PCR, cloned into a TA cloning vector, purified from the vector and then used as probes for Northern blot analysis. PCR primers were as follows: AMF forward, gcttgaccctcaaccaac; reverse, gaagtgctggtccatccagt; AMFR forward, caggaggaagtgagccagtc; reverse, agcttgctgcctaaccactc.

Phagokinetic track assay:

Phagokinetic track assay was performed according to the method reported by Albrecht-Buehler (Albrecht-Buehler et al., 1977). Briefly, gold particle suspension was prepared by mixing 18 µl of 14.5 mM AuCl₄ solution and 5 ml of 36.5 mM Na₂CO₃ solution with 11 ml double-distilled water followed by heating to boiling point and adding 1.8 ml of 0.1 % formaldehyde. Two ml of gold particle suspension was laid on the 18 X 18 mm-square glass coverslips coated with 0.1 % bovine serum albumin. The
particle-coated coverslips were placed in 35 mm plastic dishes containing DMEM/F-12 medium supplemented with 5 % FCS. Cells were seeded in the dishes and incubated for 24 h. After incubation, the coverslips were removed and fixed in 10% formaldehyde solution for 30 min and mounted on microscope slides. Phagokinetic track areas of more than 20 cells that were randomly selected were observed with the use of a microscope analyzer (Cosmo zone R500, Nikon, Japan). The experiments were done under hypoxic (1% O$_2$/5 % CO$_2$) and non-hypoxic conditions (20 % O$_2$/5 % CO$_2$). In some experiments, supernatant of the pancreatic cancer cells PCI-10 cultured in hypoxia was added in the dishes at 0, 12.5, 25, 50, and 100 %. PHI inhibitors described in the previous report (Watanabe et al., 1996), erythrose 4-phosphate (E4P) and 6-phosphogluconic acid (6PGA) (Sigma) were added into the dishes at 10, 100, and 1000 µM.

**Statistical analysis:**

Statistical analysis was done by the Mann-Whitney test.
RESULTS

_Differentially expressed genes under hypoxic conditions:_

We defined the genes expressed at more than 2-fold higher levels under hypoxic conditions than under non-hypoxic conditions as possible hypoxia-induced genes, which numbered 38. As expected, mRNAs for glycolytic enzymes and angiogenic factors were expressed at higher levels under hypoxic conditions than under non-hypoxic conditions. In the glycolytic enzymes, we found that phosphohexose isomerase (PHI) mRNA was expressed at a 2-fold higher level under hypoxic conditions than under non-hypoxic conditions. A recent report has demonstrated that AMF, which was originally identified as a molecule stimulating directional motility (chemotaxis) and random motility (chemokinesis) of melanoma cells (Liotta et al., 1986), was identical to PHI/NL (Watanabe et al, 1996). As AMF/PHI/NL secreted by tumor cells acts as a chemokinetic factor (random motility-stimulating factor) in an autocrine fashion, we focused
on this molecule that could promote the metastatic potential under hypoxic conditions.

*Expressions of AMF/PHI/NL and AMFR in a variety of cancer cells:*

We then examined the expression of AMF/PHI/NL mRNA in several cancer cell lines, including PCI-10 cells used in the DNA microarray analysis, before and after exposure to hypoxia in order to define whether the enhanced expression of AMF/PHI/NL mRNA in hypoxia was common in a variety of cancer cells. Fig. 1A shows the expression of AMF/PHI/NL mRNA in the pancreatic cancer cell lines (PCI-6, PCI-10, PCI-19, PCI-43, PCI-66, MiaPaca-2, and BxPC-3), colon cancer cell line (KM-12), lung cancer cell line (PC-6), hepatoma cell line (HepG2) and ovarian cancer cell lines (TAOV and TTOV). All the cell lines expressed AMF/PHI/NL mRNA at higher levels under hypoxic conditions than under non-hypoxic conditions, indicating that the increased expression of AMF/PHI/NL mRNA under hypoxic conditions was common in a variety of cancer cells. Next we examined the expression
of AMFR. All the cell lines examined, especially PCI-10 cells used for the examination of motility, expressed AMFR mRNA and protein (Fig. 1B and 1C), suggesting that the AMF/PHI/NL could stimulate the random motility of the cells in an autocrine fashion.

Expression of AMF/PHI/NL mRNA in HIF-1α-transfectants and dominant-negative HIF-1α-transfectants:

Fig. 2A shows the expression of AMF/PHI/NL mRNA in the HIF-1α-transfectants and the vector-transfectant under non-hypoxic conditions. The expression of AMF/PHI/NL mRNA was higher in the HIF-1α-transfectants than in the vector-transfectant. Fig. 2B shows the expression of dominant-negative HIF-1α (dnHIF-1α) mRNA. The dnHIF-1α-transfectants but not the vector-transfectant expressed the truncated dnHIF-1α mRNA in addition to the endogenous HIF-1α mRNA. Expression of AMF/PHI/NL mRNA was
enhanced after exposure to hypoxia in the vector-transfectant and the parent cells but not in the dnHIF-1α-transfectants (Fig. 2C). These results suggested that hypoxia might enhance the expression of AMF PHI/NL mRNA through the activation of HIF-1.

**Random motility:**

As shown in Fig. 3A, the random motility of PCI-10 cells increased under hypoxic conditions by more than 4-fold compared with that under non-hypoxic conditions. Furthermore, the random motility of the HIF-1α-transfectants under non-hypoxic conditions was higher than that of the vector-transfectant (Fig. 3B). Fig. 3C shows the random motility of the dnHIF-1α-transfectants under hypoxic and non-hypoxic conditions. The random motility of the vector-transfectant but not of the dnHIF-1α-transfectants was enhanced under hypoxic conditions. These results in combination with the changes in the AMF PHI/NL mRNA expression suggested that the random motility was closely correlated with the levels of AMF PHI/NL mRNA.
Next, as AMF/PHI/NL has been reported to act in an autocrine fashion, we examined the effects of supernatant of PCI-10 cells cultured under hypoxic conditions on their motility. Fig. 3D shows that the supernatant enhanced the random motility of PCI-10 cells under non-hypoxic conditions in a dose-dependent manner, indicating that the random motility-stimulating activity in the supernatant stimulated it in an autocrine fashion. In order to determine whether the presumed random motility-stimulating factor in the supernatant was identical to AMF/PHI/NL, we examined the effects of two carbohydrate phosphates, 6-phosphogluconic acid (6PGA) and erythrose 4-phosphate (E4P), which have been reported to inhibit the PHI enzymatic activity and the AMF-induced cell motility (Watanabe et al., 1996). Fig. 3D shows that 6PGA and E4P almost completely abrogated the motility-stimulating activity of the supernatant.
Figure 3E shows that 6PGA and E4P directly reduced the random motility of PCI-10 cells enhanced under hypoxic conditions.
DISCUSSION

A number of reports have demonstrated that the probability of distant metastases correlates with oxygen pressure in the tumor tissues (Gatenby et al., 1988; Brizel et al., 1996; Hockel et al., 1998; Rofstad, 2000), suggesting that hypoxia may promote metastatic potential. However, it remains poorly understood how hypoxia promotes the metastatic potential of tumor cells. In this study, we clearly demonstrated that hypoxia enhanced the AMF/PHI/NL mRNA expression in a variety of cancer cells and it also enhanced the random motility in an autocrine fashion. In accordance with our results, a recent report demonstrated that AMF/PHI/NL was identified as a hypoxia-inducible gene by a representational difference analysis using mRNA extracted from hypoxic and normoxic Capan-2, a human pancreatic cancer cell line (Yoon et al., 2001). However, it was not determined whether the enhanced expression of AMF/PHI/NL resulted in the enhanced
motility. As hypoxia is frequently observed in tumor tissues in vivo (Guillemin et al., 1997; Blancher et al., 1998), we suspected that AMF/PHI/NL might be expressed in various cancer cells in vivo. In accordance with this speculation, previous reports demonstrated that the expression of AMF/PHI/NL was found in human colorectal, bladder, esophageal, and gastric cancers and that the expression of AMF/PHI/NL correlated with the disease progression (Watanabe et al., 1991; Nabi et al., 1992). Furthermore, we found that AMF/PHI/NL was expressed also in the tumor cells of human pancreatic cancers in vivo (data not shown). Recently we have reported that most of pancreatic cancer cells, which are known to show high invasiveness and high metastatic potential in vivo, over-expressed HIF-1α proteins constitutively (Akakura et al., 2001). Those results in combination with the findings demonstrated in this study suggest that high expression of AMF/PHI/NL may be attributable to the
high invasiveness and high metastatic potential of pancreatic cancers.

It is well-known that metastasis requires coordinated activation of various factors involved in proliferation, motility, cell-to-cell and cell-to-substrate contacts, degradation of extracellular matrix, inhibition of apoptosis, and adaptation to an inappropriate tissue environment (Poste et al., 1980; Liotta et al., 1986). Our DNA microarray study showed that mRNA expressions of various angiogenic factors and glycolytic enzymes were enhanced in hypoxia in accordance with the previous reports (Vaupel et al., 1989; Semenza, 2000). Increased expression of angiogenic factors under hypoxic conditions enhances the angiogenesis that supports the survival and growth of tumor cells in the metastatic sites as well as in the primary sites (Claffey et al., 1996; Rofstad et al., 1999). Likewise increased expression of glycolytic enzymes supports
the survival and growth of tumor cells under hypoxic conditions (Malhotra et al., 1999). Accordingly, these angiogenic factors and glycolytic enzymes induced by hypoxia could enhance the metastasis in cooperation with AMF/PHI/NL. Namely, hypoxia promotes the infiltration of endothelial cells into tumor tissues in its inducing angiogenesis; the hypoxia may also induce the activation of various factors other than angiogenic factors and AMF/PHI/NL in cancer cells. We now search the possible metastasis-associated genes, which should have hypoxia-responsive elements (HRE) in the promoter region.

All together, our present results provide a new insight into the mechanisms and a possible means for control of metastasis. We now propose that the enhancement of metastatic potential may be one of hypoxic responses of tumor cells exposed to hypoxia. The findings of dominant-negative HIF-1α-transfectants suggest that the disruption of the HIF-1 pathway may be an effective
treatment for metastasis, in addition to the treatment of primary tumors through the inhibition of various genes necessary for the growth and metastasis of tumor cells in vivo, in accordance with the previous report (Kung et al., 2000).
ACKNOWLEDGEMENTS

We appreciate Dr. Hiroshi Ishikura (The First Department of Pathology, Hokkaido University School of Medicine) for providing us with a pancreatic cancer cell line. We thank Ms. M. Yanome for assistance in preparing the manuscript.
REFERENCES

Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, and Asaka M (2001) Constitutive expression of hypoxia-inducible factor-1α (HIF-1α) renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res., 61:6548-6554.

Albrecht-Buehler G (1977) Phagokinetic tracks of 3T3 cells: parallels between the orientation of track segments and of cellular structures which contain actin or tubulin. Cell, 11:395-404.

Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, Zupi G, and Del Bufalo D (2000) Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J, 14:652-660.
Blancher C and Harris AL (1998) The molecular basis of the hypoxia response pathway: tumor hypoxia as a therapy target. Cancer and Metastasis Rev, 17:187-194.

Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Pronitz LR, Samulski TV, Prosnitz LR, and Dewhirst MW (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res, 56:941-943.

Choi S, Kobayashi M, Wang J, Habellhah H, Okada F, Hamada J, Moriuchi T, Totsuka Y, and Hosokawa M (2000) Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with adriamycin. Clin. Exp. Metastasis, 18:45-50.

Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF (1996) Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells
increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 56: 172-181.

Claffey KP and Robinson GS (1996) Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev, 15:165-176.

Dang CV, and Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci, 24:68-72.

Gatenby RA, Kessler HB, Rosenblum J, Coia LR, Moldofsky PJ, Hartz WH, and Broder GJ (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys, 14:831-838.

Guillemin K and Krasnow MA (1997) The hypoxic response: huffing and HIFing. Cell, 89:9-12.

Halterman MW, Miller CC, and Federoff HJ (1999) Hypoxia-inducible factor-1alpha mediates hypoxia-induced delayed neuronal death that involves p53. J Neurosci. 19:6818-6824.
Hockel M, Schlenger K, Hockel S, Aral B, Schaffer U, and Vaupel P (1998) Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer, 79:365-369.

Kung AL, Wang S, Klco JM, Kaelin WG, and Livingston DM. (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med, 6:1335-1340.

Liotta LA (1986) Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res, 46:1-7.

Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK, and Schiffmann E (1986) Tumor cell autocrine motility factor. Proc. Natl. Acad. Sc. USA, 83:3302-3306.

Liotta LA (1988) Gene products which play a role in cancer invasion and metastasis. Breast Cancer Res, 11:113-124.

Malhotra, R. and Brosius, F.C.3rd. (1999) Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured
neonatal rat cardiac myocytes. J Biol Chem, 274:12567-17575.

Nabi IR, Watabnabe H and Raz A (1992) Autocrine motility factor and its receptor: role in cell locomotion and metastasis. Cancer Metastasis Rev, 11:5-20.

Nicolson GL (1988) Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochem Biophys Acta, 948:175-224.

Niinaka Y, Paku S, Haga A, Watanabe H, Raz A (1998) Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Res, 1998 58:2667-2674

Poste G and Fidler IJ (1980) The pathogenesis of cancer metastasis. Nature, 283:139-146.

Raijiman I and Levin B (1995) Bockus Gastroenterology 5th edn. Haubrich WS and Schaffner F (ed). WB Saunders Company: Tokyo, Pp. 2984-3001.
Rofstad EK, Danielsen T. (1999) Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer, 80:1697-707.

Rofstad EK (2000) Microenvironment-induced cancer metastasis. Int J Radiat Biol, 76:589-605.

Semenza GL (2000) Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol, 59:47-53.

Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q and Xie K (1999) Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res, 5:3711-3721.

Vaupel P, Kallinowski F and Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res, 49:6449-6465.

Wang GL, Jiang BH, Rue EA, and Semenza GL (1995) Hypoxia-inducible
factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA, 92:5510-5514.

Wang GL and Semenza GL (1996) Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol, 3:156-162.

Watanabe H, Nabi IR and Raz A (1991) The relationship between motility factor receptor internalization and the lung colonization capacity of murine melanoma cells. Cancer Res, 51:2699-2705.

Watanabe H, Takehana K, Date M, Shinozaki T and Raz A (1996) Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res, 56:2960-2963.

Yoon DY, Buchler P, Saarikoski ST, Hines OJ, Reber HA, Hankinson O. (2001) Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun
Zhong H, Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, and Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res, 59:5830-5835.
Figure Legends

Figure 1. **Expression of AMF/PHI/NL and AMFR mRNAs.**

A: AMF/PHI/NL mRNA expression. RNAs were extracted from the cells incubated under non-hypoxic (N) and hypoxic (H) conditions (20 % and 1 %, respectively) for 24 h and then Northern blot analysis was performed. B: AMFR mRNA expression. RNAs were extracted from the cells incubated under non-hypoxic (N) for 24 h and then Northern blot analysis was performed. A representative result of two different experiments is shown.

C: FACS analysis of AMFR expression. Cells were stained with anti-AMFR antibody (rat monoclonal antibody, IgM) for 1 h and then stained with second anti-rat Ig antibody for 1 h. A representative result of two different experiments is shown.

Figure 2. **Expression of AMF/PHI/NL mRNA in the transfectants:**

A: Northern blot analysis of AMF/PHI/NL mRNA in the
HIF-1α-transfectants (PCI-10/H2 and PCI-10/H3) and vector-transfectant (PCI-10/V2) under non-hypoxic conditions. AMF PHI/NL mRNA expression in PCI-10 cells under non-hypoxic (N) and hypoxic (H) conditions were shown as controls. B: Northern blot analysis of dominant negative HIF-1α (dnHIF-1α) mRNA in the transfectants. C: Northern blot analysis of AMF PHI/NL mRNA expression in the dnHIF-1α-transfectants (PCI-43/dnH3 and PCI-43/dnH7) and the vector-transfectant (PCI-43/vV3) under non-hypoxic (N) and hypoxic (H) conditions. RNAs were extracted from the cells incubated under non-hypoxic (N) and hypoxic (H) conditions for 24 h and then Northern blot analysis was performed.

Figure 3. Random motility:

Data present the mean ± SD of three different experiments. A: Random motility of the PCI-10 cells under hypoxic and normoxic...
conditions. *P<0.01; significantly different compared with the relative motility of the PCI-10 cells under normoxic conditions.

B: Random motility of the HIF-1α-transfectants under non-hypoxic conditions. *P<0.01; significantly different compared with the vector control. C: Random motility of the dnHIF-1α-transfectants and the vector-transfectant under hypoxic and non-hypoxic conditions. *P<0.05; significantly different compared with the relative motility of the PCI-43 cells under normoxic conditions. D: Random motility of PCI-10 cells under normoxic conditions in the presence or absence of the supernatant of PCI-10 cells cultured under hypoxic conditions. *P<0.01, **P<0.05; significantly different compared with the relative motility of PCI-10 cells under normoxic conditions in the absence of supernatant. †P<0.05; significantly different compared with the relative motility of PCI-10 cells in the presence of 100% supernatant. E: Random motility of the PCI-10
cells under hypoxic conditions in the presence of AMF/PHI-inhibitors. *P<0.01; significantly different compared with the relative motility of PCI-10 cells under normoxic conditions. † P<0.01; significantly different compared with the relative motility of PCI-10 cells under normoxic conditions in the absence of inhibitor.
